Escalon Medical CORP

Escalon Medical Corp. announced the completion of the sale of its AXIS platform software assets to Optos Public Limited Company for a total consideration of $3 million, receiving the first $1 million milestone payment.

Escalon Medical Corp. announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs P.C., effective April 2, 2025.

Escalon Medical Corp. reported a significantly wider net loss for Q1 2026, alongside ongoing concerns about its ability to continue as a going concern and ineffective disclosure controls.

Escalon Medical Corp. reports increased revenue and a net income for the quarter ended March 31, 2025, marking a positive shift from the previous year's loss.

Escalon Medical Corp. reports increased net revenue and a profitable quarter, driven by growth in Trek's gas products, as detailed in their Form 10-Q filing for the period ended December 31, 2024.

Escalon Medical Corp. experienced a 5.6% decrease in net revenue for the quarter ended September 30, 2024, primarily due to lower ultrasound product sales, partially offset by increased gas product sales.

Escalon Medical Corp. experienced a decrease in net revenue and a net loss for the quarter ended March 31, 2024, while also facing ongoing concerns about its ability to continue as a going concern.

Escalon Medical Corp. saw a slight increase in revenue for the six months ended December 31, 2023, but continues to face financial challenges and going concern issues.

Escalon Medical Corp. reported a slight increase in net revenue for fiscal year 2025, but auditors continue to express substantial doubt about the company's ability to continue as a going concern.

Escalon Medical Corp.'s annual report reveals a slight revenue decrease and ongoing concerns about the company's ability to continue as a going concern.

LPL Financial LLC has reported beneficial ownership of 7.9% of Escalon Medical Corp.'s common stock as of March 31, 2026.

Charles C. Newton has reported a 0% beneficial ownership in Escalon Medical Corp., indicating a full divestment of his previous stake.

Charles C. Newton has disclosed a 6.3% beneficial ownership stake in Escalon Medical Corp., holding 467,895 shares of common stock.

Newton Charles Carter has filed an amended Schedule 13G, disclosing a 6.2% beneficial ownership stake in Escalon Medical Corp., indicating a passive investment.

Charles C Newton has filed a Schedule 13G, disclosing a 6.2% beneficial ownership stake in Escalon Medical Corp.'s common stock as of May 19, 2025.